IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

CME Congresses .

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

CME Congresses .

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

CME Congresses .

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

CME Congresses .

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

CME Congresses .

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

CME Congresses .

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy

CME Congresses .

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy

September 10th- Dr. Bruno Paiva- Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

CME Congresses .

September 10th- Dr. Bruno Paiva- Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

September 4th- Dr. Raffaela Greco- High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: A prospective MIDAS consortium study

CME Congresses .

September 4th- Dr. Raffaela Greco- High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: A prospective MIDAS consortium study

July 29th- Dr. Juan Carlos Hernández-Boluda- Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

CME Congresses .

July 29th- Dr. Juan Carlos Hernández-Boluda- Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis